B Cell Lymphoma
News
Signal strength tied to potency of CAR T-cell therapy
Investigators found that chimeric antigen receptor (CAR) T cells with stronger signaling capabilities were less effective against lymphoma cells...
News
Signal strength may limit potency of CAR T-cell therapy
The “slower burning” 4-1BB CAR signal led to T cells that better retained their function in vivo and were associated with longer median survival...
News
Role of SES in childhood cancer survival disparities
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed...
News
CPI-613 receives orphan designation for PTCL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma (PTCL)....
News
Meta-analysis supports rituximab maintenance in MCL
Rituximab maintenance therapy prolonged progression-free survival. Risk of grade 3 or 4 neutropenia was increased, but risk of infection was not...
News
Real-world bleeding risk with ibrutinib
The Bruton tyrosine kinase inhibitor ibrutinib has been linked to a 20-fold increased risk of major bleeding in blood cancer patients taking...
News
Phase 1 CAR T trial for NHL launches in Cleveland
The trial will enroll 12-15 adult patients with non-Hodgkin lymphoma who have not responded to standard therapies.